WEEKLY e-ALERT [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
  • Industry News
  • BlissBio Advances Toward IPO with Focus on Next-Generation ADC Therapies(6/30/2025) (Premium)
  • GenFleet IPO Highlights Promising RAS-Targeted Drug Pipeline(6/30/2025) (Premium)
  • China Medical System to Pursue Secondary Listing on Singapore Exchange(6/30/2025) (Premium)
  • Mabwell Announces License Deal with Qilu for Albipagrastim alfa for Injection(7/1/2025) (Premium)
  • Hutchmed Receives Chinese Approval for Lung Cancer Drug Combo, Triggers $11M Milestone from AstraZeneca(7/1/2025) (Premium)
  • Biological E and China's Recbio Partner to Bring HPV9 Vaccine to India and Global Markets(7/1/2025) (Premium)
  • Healthgen Biotech IPO Approved, First STAR Market Biopharma Case Since 2022(7/1/2025) (Premium)
  • Adagene Secures Up to $25 Million from Sanofi to Advance SAFEbody Pipeline(7/1/2025) (Premium)
  • Revolution Medicines and Summit Therapeutics Launch RAS-Targeting Combo Trial in Solid Tumors(7/1/2025) (Premium)
  • ​​​​​​​Zai Lab-Backed FORTITUDE-101 Trial Hits Key Milestone in Gastric Cancer(7/1/2025) (Premium)
  • China Launches New Tax Incentives to Boost Foreign Companies' Reinvestment(7/1/2025) (Premium)
  • China's STAR Market Approves Heyuan Biotech's IPO(7/1/2025) (Premium)
  • Jinhua Conba and EVA Forge Strategic Partnership to Strengthen China-MENA Pharma Supply Chains(7/1/2025) (Premium)
  • InventisBio Launches First Phase III Trial of TYK2 Inhibitor D‑2570 in China(7/2/2025) (Premium)
  • CStone Expands Pipeline with Novel BsAb Targeting Autoimmune and Inflammatory Diseases(7/3/2025) (Premium)
  • Cloudbreak Pharma Debuts on HKEX, Raising HK$612 Million in IPO(7/3/2025) (Premium)
  • AbbVie's Venclexta Approved in China for Second-Line Treatment of del17p CLL/SLL(7/3/2025) (Premium)
  • Vaccine Sales Collapse in China as MNCs Struggle with Local Competition and Regulatory Headwinds(7/3/2025) (Premium)
  • Product/R&D News
  • CTTQ's Anlotinib Wins Approval in China for First-Line Treatment of Advanced Soft Tissue Sarcoma(6/30/2025) (Premium)
  • Cutia's Topical Finasteride Spray CU‑40102 Approved in China for Hair Loss(6/30/2025) (Premium)
  • Pfizer China's Emblaveo Cleared by NMPA for Tough Gram‑Negative Infections(6/30/2025) (Premium)
  • QL Biopharma's Dual GLP‑1/FGF21 Agonist ZT‑003 Gains IND Nod in U.S. for MASH(6/30/2025) (Premium)
  • Hengrui's Ivarmacitinib Approved in China for Severe Alopecia Areata(7/1/2025) (Premium)
  • Biokin's Iza-bren Achieves Primary Endpoint in Phase III Trial for Nasopharyngeal Carcinoma(7/2/2025) (Premium)
  • Simcere's Suvemcitug Approved in China for Platinum-Resistant Ovarian and Related Cancers(7/2/2025) (Premium)
  • China Grants Conditional Approval to Bebetter Medicine's Ifupinostat for Third-Line DLBCL(7/2/2025) (Premium)
  • NMPA Grants Marketing Approval to GeneScience's Firsekibart for Acute Gouty Arthritis Flares(7/2/2025) (Premium)
  • Betta's Tibremciclib Approved in China for Advanced HR+/HER2– Breast Cancer(7/2/2025) (Premium)
  • HanchorBio and Henlius Ink Major Licensing Deal for I/O Candidate HCB101(7/2/2025) (Premium)
  • Dizal's Lung Cancer Pill Gains FDA Nod, Challenging Rivals in EGFR Exon 20 Market(7/3/2025) (Premium)
  • Akeso Launches Clinical Trials for First Bispecific ADC(7/3/2025) (Premium)
  • Belief BioMed Unveils 4-Year Follow-Up Data for Hemophilia B Gene Therapy(7/3/2025) (Premium)
  • CTTQ's Homegrown rFVIIa Wins NMPA Approval for Bleeding Disorders(7/3/2025) (Premium)
  • Hengrui Medicine Gains NMPA Approval for Novel Dry Eye Treatment SHR8058(7/3/2025) (Premium)
  • Eli Lilly's Tirzepatide Approved in China for Treatment of Obstructive Sleep Apnea in Obese Patients(7/3/2025) (Premium)
  • Home | Contact Us | Subscribe
  • © Wicon International Group